Use of Artificial Intelligence to Identify New Mechanisms and Approaches to Therapy of Bone Disorders Associated With Chronic Kidney Disease.

artificial intelligence chronic kidney disease in silico clinical trials mathematical modeling osteoporosis

Journal

Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047

Informations de publication

Date de publication:
2022
Historique:
received: 02 11 2021
accepted: 28 02 2022
entrez: 11 4 2022
pubmed: 12 4 2022
medline: 12 4 2022
Statut: epublish

Résumé

Chronic kidney disease (CKD) leads to clinically severe bone loss, resulting from the deranged mineral metabolism that accompanies CKD. Each individual patient presents a unique combination of risk factors, pathologies, and complications of bone disease. The complexity of the disorder coupled with our incomplete understanding of the pathophysiology has significantly hampered the ability of nephrologists to prevent fractures, a leading comorbidity of CKD. Much has been learned from animal models; however, we propose in this review that application of multiple techniques of mathematical modeling and artificial intelligence can accelerate our ability to develop relevant and impactful clinical trials and can lead to better understanding of the osteoporosis of CKD. We highlight the foundational work that informed our current model development and discuss the potential applications of our approach combining principles of quantitative systems pharmacology, model predictive control, and reinforcement learning to deliver individualized precision medical therapy of this highly complex disorder.

Identifiants

pubmed: 35402468
doi: 10.3389/fmed.2022.807994
pmc: PMC8990896
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

807994

Informations de copyright

Copyright © 2022 Gaweda, Lederer and Brier.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

PLoS One. 2016 Jan 25;11(1):e0146801
pubmed: 26808154
Osteoporos Int. 2014 Oct;25(10):2359-81
pubmed: 25182228
J Am Soc Nephrol. 2003 Jul;14(7 Suppl 2):S148-53
pubmed: 12819321
Artif Intell Med. 2015 Jun;64(2):131-45
pubmed: 25976208
Bone. 1996 May;18(5):397-403
pubmed: 8739896
J Pharmacokinet Pharmacodyn. 2022 Feb;49(1):19-37
pubmed: 34671863
Semin Nephrol. 2018 Jul;38(4):397-409
pubmed: 30082059
J Am Soc Nephrol. 2014 Jan;25(1):159-66
pubmed: 24029429
J Biomed Inform. 2018 Sep;85:30-39
pubmed: 30016722
Clin J Am Soc Nephrol. 2010 May;5(5):814-20
pubmed: 20185598
Kidney Int Suppl. 2009 Aug;(113):S1-130
pubmed: 19644521
J Clin Pharmacol. 2012 Jan;52(1 Suppl):45S-53S
pubmed: 22232752
Clin J Am Soc Nephrol. 2020 Oct 7;15(10):1389-1391
pubmed: 32938618
Am J Physiol Renal Physiol. 2021 Feb 1;320(2):F203-F211
pubmed: 33308018
Clin Nephrol. 2018 Oct;90(4):276-285
pubmed: 30049300
Science. 2018 Dec 7;362(6419):1140-1144
pubmed: 30523106
Clin J Am Soc Nephrol. 2009 Aug;4(8):1302-11
pubmed: 19541818
Int J Endocrinol. 2017;2017:1659071
pubmed: 29387084
Am J Kidney Dis. 2022 Mar;79(3):427-436
pubmed: 34419519
Clin J Am Soc Nephrol. 2020 Oct 7;15(10):1445-1454
pubmed: 32938617
Kidney Int Suppl (2011). 2017 Jul;7(1):1-59
pubmed: 30675420
Bone. 2010 Jan;46(1):49-63
pubmed: 19732857
CPT Pharmacometrics Syst Pharmacol. 2012 Nov 14;1:e14
pubmed: 23835796
Bone Rep. 2015 Apr 17;2:59-67
pubmed: 28377955
Kidney Int. 2004 Mar;65(3):904-17
pubmed: 14871410
Physiol Rep. 2019 Apr;7(7):e14045
pubmed: 30927339

Auteurs

Adam E Gaweda (AE)

Division of Nephrology, Department of Medicine, University of Louisville School of Medicine, Louisville, KY, United States.

Eleanor D Lederer (ED)

Medical Services, VA North Texas Health Sciences Center, Dallas, TX, United States.
Division of Nephrology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States.
Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, TX, United States.

Michael E Brier (ME)

Division of Nephrology, Department of Medicine, University of Louisville School of Medicine, Louisville, KY, United States.
Research Service, Robley Rex VA Medical Center, Louisville, KY, United States.

Classifications MeSH